AIIMS Director Dr Randeep Guleria said on August 6 that no clear mortality benefit of convalescent plasma therapy was seen during a trial conducted among 30 COVID-19 patients
An interim analysis of a randomised controlled trial done at the All India Institute of Medical Sciences (AIIMS) to assess the efficacy of convalescent plasma therapy has revealed it does not reduce mortality risk among COVID-19 patients.
AIIMS director Dr Randeep Guleria told PTI on August 6 that no clear mortality benefit of convalescent plasma therapy was seen during a trial conducted among 30 COVID-19 patients.
During the trial, one group of patients were given convalescent plasma therapy along with the standard supportive treatment while the other group only received standard treatment.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
The number of fatalities recorded in both the groups was equal and there was not much clinical improvement in the condition of patients, he said.
"However, this is just an interim analysis and we need to do a more detailed evaluation to see if any sub-group may benefit from plasma therapy," Guleria said.
The convalescent plasma therapy involves taking antibodies from a recovered COVID-19 patient and transfusing those into an active novel coronavirus infected patient to help them fight the infection.
He also underlined that plasma has to be tested for its safety and should have sufficient antibody to be useful to COVID-19 patients.
The efficacy of convalescent plasma therapy in moderate to severe coronavirus-infected patients was discussed in the third National Clinical Grand Rounds (CGR) on COVID-19 held on Wednesday.
"Plasma is safe. As far as its efficacy is concerned, we do not have a green signal yet. So the clinical use has to be very judicious and within the ambit of national guidelines," Dr Monish Soneja, Additional Professor, Medicine Department, AIIMS, said at the webinar.
Convalescent plasma therapy has been listed as an investigational therapy for off-label use in coronavirus infected patients because as of now there is no conclusive evidence for its efficacy, Soneja said.
About the initial findings of the randomised controlled trial, Soneja said, "Convalescent plasma is not a magic bullet."
It may be used particularly in early moderate stage of the disease. There may be a subset of patients with certain characteristics who may benefit from plasma, he said, adding, “This is a work in progress as we do not know those characteristics”.
The findings highlight that relatives of the patients should not insist on plasma therapy until and unless the treating doctor considers the patient fit for it and where he may think that the mode of treatment would be beneficial, Dr Neeraj Nischal, associate Professor in the department of medicine at AIIMS, said.
He said even if the therapy has some role, then that is in the early stage of the disease. But for plasma therapy to be effective, plasma must contain a sufficient amount of neutralising antibody against that infection, the doctor said.
"This therapy also carries risks such as inadvertent transfer of blood-borne infections and reactions to serum constituents, including immunological reactions such as serum sickness, that may worsen the clinical condition," Nischal said.
According to the Clinical Management Protocols for COVID-19 issued by the Union health ministry, off-label convalescent plasma may be considered for COVID-19 patients with moderate disease who are not improving, which means oxygen requirement is progressively increasing, despite the use of steroids.
Follow our coverage of the coronavirus crisis here